至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Modified pegRNAs mitigate scaffold-derived prime editing by-products

Nature Communications. 2025-04; 
Panagiotis Antoniou, Louis Dacquay, Hanna Mårtensson, Katja Madeyski-Bengtson, Anna-Lena Loyd, Anna Shiriaeva, Euan Gordon, Salman Mustfa, George Thom, Pei-Pei Hsieh, Saša Šviković, Mike Firth, Nina Akrap, Marcello Maresca & Martin Peterka AstraZeneca
Products/Services Used Details Operation
Gene Synthesis PE6d6 and PE**9 and their WT-Cas9 (H840) variants PEn6d and PEn** were generated by gene synthesis (GenScript). Synthetic pegRNAs with abasic spacers were synthesized by Horizon Discovery or GenScript. Get A Quote

摘要

Prime editors (PEs) employ reverse transcriptase (RT) to install genomic edits using a template within the prime editing guide RNA (pegRNA). RT creates a 3’ genomic flap containing the intended edit. However, reverse transcription can continue beyond the template, incorporating the pegRNA scaffold sequence into the 3’ flap. These scaffold-derived by-products can be installed alongside the intended edit, reducing prime editing precision. Here, we develop a method that prevents RT from accessing the scaffold, thereby mitigating such by-products. We demonstrate that an internal abasic spacer or 2’-O-methylation within the pegRNAs terminates RT at the end of the template. This prevents scaffold-derived sequen... More

关键词